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Background: Galectin-3, a member of the beta-galactoside-binding lectin family, is a multifunctional protein with
various biological functions, including the proliferation and differentiation of tumor cells, angiogenesis, cancer
progression, and metastasis. We aimed to clarify if expression of galectin-3 is related to the clinicopathological
characteristics and prognosis of hepatocellular carcinoma (HCC) patients, and to explore the possible mechanisms
of galectin-3 in hepatocellular carcinoma.
Methods: First, we investigated galectin-3 mRNA and protein expression by using RT-PCR and Western blotting.
Second, tissues from 165 HCC patients were used to evaluate clinicopathological characteristics and prognosis
through immunohistochemical analyses. Furthermore, the functions of galectin-3 were analyzed with respect to the
proliferation, cell cycle,apoptosis, migration, and invasion of HCC cell lines. Finally, we analyzed galectin-3 expression
and micro-vessel density (MVD) by immunohistochemistry (IHC) to find its correlation with angiogenesis in
Hepatocellular Carcinoma. Flow cytometer was used to explore apoptosis and Western-blot was used to detect the
pathway proteins of apoptosis.
Results: Galectin-3 showed high expression at the mRNA and protein levels in HCC cancer tissues and cell lines.
Clinicopathological analyses revealed that increased expression of galectin-3 in tumors was closely associated with
a poor prognosis. Galectin-3 knockdown by siRNA significantly inhibited cell growth, migration, and invasion, and
induced apoptosis in HCC cells in vitro, whereas galectin-3 overexpression promoted cell growth, migration, and
invasion. Correlation analysis of galectin-3 expression and micro-vessel density (MVD) showed that galectin-3
expression in tumor cells stimulates angiogenesis. The observed regulation of cell apoptosis was accompanied by
the galectin-3-mediated modulation of caspase3 signaling pathways in HCC cells.
Conclusions: These data suggest that galectin-3 plays an important part in HCC progression and may serve as a
prognostic factor for HCC.
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Hepatocellular carcinoma (HCC) is one of the most
prevalent and lethal malignancies worldwide. HCC is the
second most frequent cause of cancer deaths and the
fifth most commonly diagnosed cancer in the world, and
is particularly prevalent in southeastern Asia and sub-
Saharan Africa [1,2]. Options for curative treatment for* Correspondence: xiajch@mail.sysu.edu.cn
†Equal contributors
1State Key Laboratory of Oncology in Southern China and Department of
Experimental Research, Sun Yat-sen University Cancer Center, 651 Dongfeng
Road East, Guangzhou 510060, PR China
Full list of author information is available at the end of the article
© 2014 Jiang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.early-stage HCC are surgery, transarterial chemoemboli-
zation (TACE), chemotherapy, biotherapy and radiother-
apy [3]. The outcome and prognosis of HCC are
disappointing. Only 10–20% of tumors are resectable at
the time of diagnosis, and the five-year survival is poor
even compared with other gastrointestinal malignancies
[4]. Hepatocarcinogenesis is a multifactorial and multi-
step process that involves activating oncogenes and in-
activating tumor suppressor genes at different stages
during the progression of HCC [5-7].
The galectins are a family of beta-galactoside-binding
proteins implicated in the modulation of cell–cell andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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identified in mammals. Galectin-3 is expressed widely
and is structurally unique. It comprises three distinct do-
mains: a short NH2-terminal domain containing a serine
phosphorylation site; a repeated collagen-like sequence;
and a COOH-terminal domain containing a single carbo-
hydrate recognition-binding domain [10,11]. Galectin-3 is
a multifunctional protein implicated in various biological
functions, including: the adhesion, proliferation and differ-
entiation of tumor cells, angiogenesis, cancer progression
and metastasis [12]. Cytosolic galectin-3 is targeted to the
plasma membrane and released into the extracellular
space, where it participates in the regulation of the migra-
tion and adhesion of cells [13]. Galectin-3 is also targeted
to the nucleus, where it plays a part in pre-mRNA splicing
and activation of diverse transcription factors [14].
Galectin-3 has been found to be correlated to several can-
cers, including mesothelioma [15] as well as cancer of
breast [16], gastrointestinal system [17], and colon [18].
Shimosegawa et al. [19] reported that in HCC, galectin-3
expression was correlated with histological differentiation
and vascular invasion, and that patients who expressed
galectin-3 tended to relapse earlier and had poorer overall
survival. However, the number of cases in their study was
relatively small (52 patients). Hence, the function of
galectin-3 in HCC has not been fully characterized.
We aimed to evaluate the correlations between the clini-
copathological features and galectin-3 expression in a lar-
ger group of Chinese HCC patients (165 cases). We also
attempted to analyze the prognostic value of galectin-3 ex-
pression. Moreover, we assessed the effect of galectin-3 on
the progression of HCC by assessing the effect of knock-
down and overexpression of galectin-3 on the prolifera-
tion, migration, invasion, cell cycle and apoptosis in HCC
cells in vitro.
Materials and methods
Ethical approval of the study protocol
This study was approved by the Ethics Committee of the
Cancer Center of Sun Yat-sen University (Guangdong,
China). Written informed consent was obtained from
each patient.
Cell culture
The human HCC cell lines, HepG2 (well differentiated,
low metastatic potential), Hep3B (well differentiated, low
metastatic potential), and Human liver adenocarc -inoma
Endothelial cell line, Sk-Hep1 were obtained from the
American Type Culture Collection (Manassas, VA, USA).
Huh7 cells (well differentiated, low metastatic potential)
were obtained from the Riken Cell Bank (Ibaraki, Japan).
Bel-7402 cells (moderate differentiated, low metastatic po-
tential) and the normal liver cell line LO2 were obtained
from the Committee of Type Culture Collection of theChinese Academy of Sciences (Shanghai, China). All cells
were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS) in 5% CO2 at 37°C.
Patients and tumor tissue samples
Tissue samples, including HCC tumor tissues and adja-
cent non-cancerous tissues (n = 44), were obtained from
patients who had resection of primary HCC in the Can-
cer Center of Sun Yat-sen University between 2011 and
2012. None of these patients had received preoperative
chemotherapy or radiotherapy. After resection, matched
fresh tissues were immersed immediately in RNAlater®
(Ambion, Austin, TX, USA), kept overnight at 4°C, then
stored at −80°C until RNA isolation. A total of 165
paraffin-embedded HCC samples were obtained from
patients who underwent hepatectomy at the Cancer
Center of Sun Yat-sen University between 2001 and
2004. Follow-up was in our outpatient department, and
involved clinical and laboratory examinations every
3 months for the first 2 years, every 6 months during
the third to fifth years, and annually for an additional
5 years or until death, whichever occurred first. Overall
survival (i.e., time from surgery to death or final follow-
up) was used as a measure of prognosis. Histological
types were assigned according to classification criteria
set by the World Health Organization.
RNA preparation and protein extraction
Total RNA was extracted by using Trizol solution (Invi-
trogen, Shanghai, China) according to manufacturer’s in-
structions. Total protein was extracted with RIPA buffer
(Beyotime, Shanghai, China) according to the manufac-
turer’s protocol. RNA and protein samples were stored
at −80°C until use.
Real-time quantitative reverse transcription-polymerase
chain reaction (RT-PC R)
Real-time PCR amplification was undertaken with an
ABI 7900HT Real-time PCR system (Life Technologies,
Carlsbad, CA, USA). The primers used for amplifying
galectin-3, caspase3, caspase9, PARP, BAX, Bcl-2, GAPDH
were selected. That is, for galectin-3, they were: forward,
5′-ACGAGCGGAAAATGGCAGA-3′; and reverse, 5′-
GATAGGAAGCCCCTGGGTAGC-3′. For glyceraldehyde-
3-phosphatedehydroge nase (GAPDH), forward 5′-CTCC
TCCTGTTCGACAGTCAGC-3′, and reverse, 5′-CCCA
ATACGACCAAATCCGTT-3; for caspase3, forward 5′-
ATCTCGG TCTG GTACAGATGTCGAT-3′, and reverse
5′-TGAATTTCGCCAAGAATAATACCA-3′; for caspase9,
forward 5′-GCCATGGACGAAGCGGATCGGC-3′, re-
verse 5′-GGC CTGGATGAAGAAGAGCTTGGG-3′; for
PARP, forward primer 5′-CGGAGTCTT CGGATAAGC
TCT-3′, reverse primer 5′-TTTCCATCAAACATGG GC
GAC-3′; for BAX, forward primer 5′-CCCGAGAGGTC
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TGGTTCTGAT-3′; for Bcl-2, forward primer 5′-GGTGG
GGTCA TGTGTGTGG-3′, reverse primer 5′-CGGTT
CAGGTACTCAGTCATCC-3′. The PCR was carried out
in a final volume of 15 μL, consisting of 7.5 μL of 2× SYBR
Green master mix (Invitrogen), 2 μL of each 5′- and 3′-
primer (1.5 pmol/μL), 0.5 μL of the sample cDNA, and
5 μL water. The PCR conditions were 95°C for 10 min, one
cycle, followed by 95°C for 30 s and 60°C for 60 s, 45 cycles.
The relative expression levels of galectin-3, caspase3,
caspase9, PARP, BAX, Bcl-2 were normalized to that of the
internal control gene, GAPDH. Data were analyzed using
the comparative threshold cycle (2– –ΔΔCT) method.
Immunohistochemistry
Isolated tumors were fixed in 10% neutral buffered for-
malin for 48 h and embedded in paraffin according to
standard protocols. Sections (thickness, 4 μm) were
deparaffinized and rehydrated in a graded series of alco-
hol solutions. For antigen retrieval, slides were immersed
in ethylenediamine tetra-acetic acid (EDTA; 1 mmol/L,
pH8.0) and boiled for 15 min in a microwave oven. En-
dogenous peroxidase acti- vity was blocked in 3% H2O2
at room temperature for 15 min, and non-specific bind-
ing was abolished by 5% bovine serum albumin (BSA)
for 30 min. Sections were then stained with anti-galectin-3
(rabbit anti-galectin-3 polyclonal antibody; 1:250 dilution;
Abcam, Cambridge, UK) antibody, anti-CD34 (rabbit anti-
CD34 polyclonal antibody; 1:400 dilution; Gene Tech,
Shanghai, China) antibody at 4°C overnight. After washing
with phosphate-buffered saline (PBS), sections were incu-
bated with horseradish peroxidase (HRP)-conjugated sec-
ondary antibody (Envision Detection kit, GK500705, Gene
Tech, Shanghai, China) at room temperature for 30 min.
After washing thrice with PBS, antibody complexes were
colored with 3, 3′-diamino benzidine and then counter-
stained with hematoxylin. Slides were dehydrated and
evaluated.
Semi-quantitative method
The total galectin-3 immunostaining score was calcu-
lated as the sum of the positively stained tumor cells and
staining intensity. Briefly, the percentage of positive
staining was scored as “0” (<5%, negative), “1” (5–25%,
sporadic), “2” (25–50%, focal), or “3” (>50%, diffuse).
Staining intensity was scored as “0” (no staining), “1”
(weak staining), “2” (moderate staining), or “3” (strong
staining). Both the percentage of positive cells and the
staining intensity were evaluated under double-blind
conditions. The total immunostaining score was calcu-
lated as the value of percent positivity score × staining
intensity score, and ranged from 0 to 9. We defined
galectin-3 expression levels as: “–” (score 0–1), “+” (2–
3), “++” (4–6) and “+++” (>6). Based on their levels ofgalectin-3 expression, patients were divided into two
groups: low galectin-3 (“–” and “+”) and high galectin-3
(“++” and “+++”). For intratumoral MVD assessment,
micro-vessels were recorded by counting CD34-positive
stained endothelial cells according to the international
consensus on the methodology and criteria of evaluation
of angiogenesis quantification in solid tumors. After
scanning the whole section at low magnifications (100×),
ten tumor areas with the greatest number of distinctly
highlighted micro-vessels (hot spot) were selected. The
value of MVD was evaluated by the average of ten 200 ×
field micro-vessel counts. Data were shown as mean ±
SD. The score assessment was performed independently
by two pathologists blinded to the clinical parameters.Western blotting
HCC samples (tumor and adjacent non-tumor tissues)
and cell lines were lysed in RIPA lysis buffer. Lysates
were harvested by centrifugation (12,000 rpm for 20 min
at 4°C. Protein samples (≈30 μg) were resolved in 12%
sodium dodecyl sulfate polyacrylamide gel for electro-
phoresis and transferred to a polyvinylidene difluoride
(PVDF) membrane. After blocking non-specific binding
sites for 60 min with 8% non-fat milk, membranes were
incubated overnight at 4°C with a rabbit polyclonal anti-
body against galectin-3 (1:1,000 dilution; Abcam), cas-
pase3 (1:500 dilution, cell signaling technology), caspase9
(1:500 dilution, cell signaling technology), PARP (1:500 di-
lution, cell signaling technology), BAX (1:500 dilution;
Proteintech Group), Bcl-2 (1:1000 dilution; Proteintech
Group) or GAPDH (1:10,000 dilution; Proteintech Group).
Membranes were washed four times with TRIS-buffered
saline with Tween-20 for 10 min. After washing, mem-
branes were probed with HRP-conjugated secondary anti-
body and visualized using a chemiluminecent system (Cell
Signaling Technology, Danvers, MA, USA). Band intensity
was measured by Quantity One software (BioRad, Hercules,
CA, USA).RNA oligonucleotides and cell transfection
For transient transfection experiments, certain small inter-
fering ribonucleic acid (siRNA) molecules were used. That
is, for galectin-3-siRNA: sense, 5′-GUACA AUCAUCG
GGUUAAATT-3′ and antisense, 5′-UUUAACCCGAUG
AUUGUACTT-3′. For the negative control: sense, 5′-UU
CUCCGAACGUGUCACGUTT-3′ and anti- sense, 5′-
ACGUGACACGUUCGGAGAATT-3′. The siRNAs were
synthesized by GenePharma (Shanghai, China). Cells at
around 70% confluence were transfected with the indi-
cated siRNA using Lipofectamine RNAiMax reagent (Invi-
trogen) according to manufacturer’s instruction. 72 hours
after transfection, cells were detached with trypsin/EDTA,
suspension, and allowed to grow overnight before
Jiang et al. Journal of Translational Medicine 2014, 12:273 Page 4 of 14
http://www.translational-medicine.com/content/12/1/273treatment. Knockdown efficiency was evaluated by west-
ern blotting.
Recombinant Lentivirus vector construction and tumor
cell infection
The galectin-3-overexpressing recombined Lentivirus
vector and the control vector were constructed by Gene-
Pharma (Shanghai, China). Lentiviral infection was per-
formed by adding virus solution to Hep3B cells in the
presence of 5 μg/ml polybrene (Sigma-Aldrich, St. Louis,
MO, USA). After infection for 48 h, the cells were se-
lected in the presence of 2 μg/ml puromycin, and
puromycin-resistant cells were collected and cultured.
The stable cell lines were specified as Hep3B-galectin-3
and Hep3B-mock, respectively.
Cell proliferation assay
Cell growth rates were measured with a (3-(4, 5-
dimethylthiazol-2-yl) -5-(3-carboxy methoxyphenyl)-2-(4-
sulfophenyl)-2H-tetr-azolium) (MTS) cell proliferation
assay. Cells were plated in triplicate in 96-well plates at
2500 cells per well. At each time point, the medium was
removed and cells incubated with 20 μL of MTS (5 mg/
mL; Sigma-Aldrich, St Louis, MO, USA) for 4 hours in 5%
CO2 at 37°C. Finally, the optical density of formazan was
measured using a microplate reader at 490 nm. Three in-
dependent experiments were performed to analyze the cellFigure 1 Expression of galectin-3 mRNA and protein in human primary
PCR and Western blotting. (A) The protein transcript levels of galectin-3 in t
normal liver cell line LO2. (B) The relative mRNA expression of galectin-3 was
(p = 0.039). (C) Galectin-3 protein expression was increased in tumor tissues cogrowth. Statistical analyses were carried out using the
two-tailed unpaired Student’s t-test.
Cell cycle assay
HCC cells transfected with gal-siRNA, NC, galectin-3-
overexpression were collected after 36 h, washed twice
in PBS, and fixed in 75% ethanol overnight at −20°C.
Fixed cells were washed with ice-cold PBS once, resus-
pended in 500 μL PBS and 20 μL RNaseA, and then in-
cubated in a 37°C water-bath for 30 min. Cells were
stained with propidium iodide (PI; Bestbio, Shanghai,
China) at 4°C in the dark for 30–60 min. Flow cytometry
data were analyzed using Beckman Coulter (Fullerton,
CA, USA) software.
Apoptosis assay
HCC cells transfected with gal-siRNA, NC, galectin-3-
overexpression were collected after 72 h. This was fol-
lowed by trypsinization, centrifugation and washing with
ice-cold PBS twice. Cells were then resuspended in
400 μL 1× binding buffer, incubated with 5 μL AnnexinV-
fluorescein isothiocyanate and 10 μL PI for 15 min in the
dark at 2–8°C. The numbers of stained cells were ana-
lyzed by a flow cytometer (Beckman Coulter). Each ex-
periment was conducted in triplicate. Statistical analyses
were carried out using the two-tailed unpaired Student’s
t-test.HCC cell lines and tissues as evaluated by real-time quantitative
he Hep3B, Huh7, HepG2, and Bel7402 HCC cells were higher than in the
higher in 44 HCC tumor tissues than in adjacent non-tumor tissues
mpared with adjacent non-tumorous tissues (p = 0.002).
Figure 2 Decreased galectin-3 and CD34 expression in surgical
specimens of primary hepatocellular carcinoma (n = 165)
detected by immunohistochemistry. (A1-4) Immunohistochemical
staining for galectin-3 expression in human hepatocellular carcinoma.
(A1) Adjacent non-tumorous tissues. (A2) Poorly differentiated
hepatocellular carcinoma. (A3) Moderately differentiated hepatocellular
carcinoma. (A4) Well-differentiated hepatocellular carcinoma.
(A5-6) Immunohistochemical staining for CD34 antigen in human
hepatocellular carcinoma. Original magnification for A1–A6, ×200.
(B) Based on the results of immunohistochemical staining, the HCC
patients (n = 165) were divided into high galectin-3 expression (n = 135)
and low galectin-3 expression (n = 30) after resection. Log-rank test
revealed that patients in the low-expression group exhibited significantly
better survival than those in the high-expression group (P < 0.01).
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Invasion assays were carried out using transwell mem-
brane filter inserts (diameter, 6.5 mm; pore size, 8 μm)
in a 24-well tissue culture plate. Briefly, transfected
Bel-7402, HepG2, Huh7 and Hep3B cells were har-
vested at 24 h and resuspended in serum-free RIPM
1640. Cells (1 × 105/well) in 200 μL of growth medium
without FBS were added to the upper chamber, and
the bottom chamber was filled with 500 μL of growth
medium containing 10% FBS. After 48 h, non-
migrating cells were removed from the top of the filter
with a cotton swab. Invading cells on the bottom of
the filter were fixed with methanol, stained with 0.5%
crystal violet, and counted. Stained cells at 10 random
fields were counted using an inverted microscope.
Each experiment was conducted in triplicate. Statistical
analyses were carried out using the two-tailed un-
paired Student’s t-test.
Wound-healing assay
We assessed the migration of control- and galectin-3-
siRNA, galectin-3-overex -pression transfected cells
using an in vitro wound-healing assay. HepG2, Bel-7402,
Hep3B cells (1 × 105cells/well) transfected with gal-siRNA,
galectin-3-overexpression and negative control were
plated in six-well plates, wounded by scratching with a
pipette tip, then incubated with RIPM 1640 without 10%
FBS for 24 h in 5% CO2 at 37°C. All experiments were car-
ried out in triplicate.
Cell migration assay
The cell migration assays were performed in a chamber
system consisting of polycarbonate membrane inserts
with an 8-μm pore size (Corning, USA) placed in 24-
well cell culture insert companion plates. The migration
assay was conducted at 48 hours after the HepG2, Bel-
7402, Hep3B and Huh7 cells were infected with siRNA,
negative control, and galectin-3-overexpression. The
cells (in 200 μL of growth medium without FBS) were
placed in the upper chamber and 500 μL of growth
medium with 5% FBS was placed in the lower chamber.
The cells were incubated at 37°C for 24 hours. Following
the incubation, the insert membranes were fixed with
75% methanol for 30 minutes, stained with 0.5% crystal
violet, and counted. The stained cells were counted
under an inverted microscope (10 fields per membrane).
Each experiment was performed in triplicate. Statistical
analyses were carried out using the two-tailed unpaired
Student’s t-test.
Statistical analyses
Statistical analyses were conducted using SPSS version
17.0 (SPSS, Chicago, IL, USA). The paired-samples t-test
was used to investigate the differences in expression of
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sue samples. The correlation between galectin-3 expres-
sion and clinicopathological features was evaluated by
the χ2 test. Overall survival was calculated using the
Kaplan–Meier method and the log-rank test was used
for comparison. The Cox proportional hazards regres-
sion model was used for univariate and multivariate ana-
lyses. The results were expressed as mean ± SD and
analyzed using the Students’ t-test. Differences were
considered significant at p < 0.05.Table 1 Relationship between galectin-3 and CD34 expression
hepatocellular carcinoma
Clinicopathologic variable N Galectin-3 expression
Low High
All cases 165 30 (18.2%) 135 (
Age (years)
<50 93 20 (21.5%) 73 (7
≥50 72 10 (13.9%) 62 (8
Sex
Male 133 23 (17.3%) 110 (
Female 32 7 (21.9%) 25 (7
Tumor size(cm)
<5 67 11 (16.4%) 56 (8
≥5 98 19 (19.4%) 79 (8
Histological differentiation
Good 41 7 (17.1%) 34 (8
Moderate 95 17 (17.9%) 78 (8
Poor 29 6 (20.7%) 23 (7
Liver cirrhosis
No 27 6 (22.2%) 21 (7
Yes 138 24 (17.4%) 114 (
HBsAg
Negative 17 3 (17.6%) 14 (8
Positive 148 27 (18.2%) 121 (
Serum alpha fetoprotein
<25 μg/L 47 20 (42.6%) 27 (5
≥25 μg/L 118 10 (8.5%) 108 (
Distant metastasis
No 152 30 (19.7%) 122 (
Yes 13 0 (0%) 13 (1
Presence of intrahepatic metastasis
No 138 23 (16.7%) 115 (
Yes 27 7 (25.9%) 20 (7
Recurrence
No 154 28 (18.2%) 126 (
Yes 11 2 (18.2%) 9 (81Results
Galectin-3 mRNA and protein expression in HCC
Firstly, HCC cell lines and primary HCC tissue samples
were used to examine galectin-3 expression by quantita-
tive real-time PCR and Western blot analyses. Western
blot analyses confirmed that the protein transcript levels
of galectin-3 in all four HCC cell lines were higher than
the normal liver cell line LO2 (Figure 1A). Additionally,
in 44 paired primary HCC tissue samples, an increased






81.8%) 35.80 ± 20.82 0-77
0.146 0.952
8.5%) 34.64 ± 20.83 1-77
6.1%) 37.28 ± 20.85 0-76
0.353 0.926
82.7%) 36.63 ± 20.72 0-77
8.1%) 32.33 ± 21.21 1-74
0.393 0.103
3.6%) 37.50 ± 19.45 0-77
0.6%) 34.63 ± 21.72 2-76
0.993 0.217
2.9%) 39.89 ± 21.51 3-77
2.1%) 33.43 ± 19.48 0-75
9.3%) 37.74 ± 24.05 7-76
0.361 0.621
7.8%) 37.86 ± 21.43 11-77
82.6%) 35.39 ± 20.75 0-76
0.627 0.139
2.4%) 30.61 ± 18.38 1-76
81.8%) 36.39 ± 21.06 0-77
<0.01 0.843
7.4%) 39.61 ± 20.62 0-77
91.5%) 34.27 ± 20.79 1-76
0.128 0.252
80.2%) 35.38 ± 20.55 0-77
00%) 40.60 ± 24.15 10-76
0.254 0.82
83.3%) 34.97 ± 20.73 0-77
4.1%) 40.03 ± 21.14 3-75
0.999 0.256
81.8%) 35.62 ± 20.53 0-77
.8%) 38.21 ± 25.54 3-76
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cent non-tumor tissues, as evidenced by quantitative
real-time PCR analyses (P = 0.039; Figure 1B). This ten-
dency was also verified at the protein level with western
blot analyses (P = 0.002; Figure 1C).
Association of galectin-3 with the clinicopathological
features of HCC
To confirm the prognostic significance of galectin-3 for
the early diagnosis and prediction of outcome in HCC,
we analyzed the correlation between expression of
galectin-3 and clinicopathological and survival parame-
ters. An immunohistochemistry analysis revealed that
galectin-3 was abundantly accumulated in the cytoplasm
of Hepatocellular cancer cells. We found 135 samples
with a high expression of galectin-3 (immunostaining
levels of “++” and “+++”) (Figure 2A). The relationship
between the clinicopathological features of HCC and
galectin-3 expression is summarized in Table 1. We ob-
served that galectin-3 expression was positively corre-
lated with serum levels of AFP (P < 0.01). However, there
was no apparent relationship between galectin-3 expres-
sion and other clinicopathological parameters, including
differentiation status (both P > 0.05).
However, high galectin-3 expression was significantly
associated with a poor prognosis (Figure 2B). Overall
survival was significantly lower in the group with high
galectin-3 expression than the group with low galectin-3
expression (135 vs. 30 P < 0.01). Further univariate and
multivariate analyses were employed to compare the as-
sociations of galectin-3 expression with other clinicopath-
ological parameters. Overall survival was significantly
correlated with galectin-3 expression (P < 0.01), CD34
(P = 0.049), tumor size (P = 0.005), and histological dif-
ferentiation (P = 0.032), but not with sex, age, cirrhosis







Tumor size 1.808 1.197–2.732
Histologic grade 1.408 1.030–1.925
Liver cirrhosis 1.007 0.590–1.717
HBsAg status 0.963 0.515–1.801
Serum 1.24 0.802–1.916
Alpha fetoprotein
Distant metastasis 1.548 0.846–2.833
ap <0.05.serum level of the surface antigen of the hepatitis B
virus (HBSAg), metastasis, or recurrence (Table 2).
Thus, galectin-3 may be a useful maker for predicting
the overall survival of HCC patients.
Correlation between MVD and clinicopathologic factors in
patients with HCC
Intratumoral MVD was quantified by counting CD34-
positive endothelial cells in the same series of HCC tis-
sues shown in Figure 2A and the staining intensity of
MVD ranged broadly from 0 to 77 micro-vessels/200 ×
magnification fields. Although a statistically significant
difference was not detected, high MVD tended to be as-
sociated with histological differentiation (P = 0.217) and
tumor size (P = 0.103), and there was no statistically sig-
nificant correlation between MVD and any other clinico-
pathologic factors (Table 1). However, MVD showed a
significant difference in the low and high galectin-3
group (24.9 ± 18.1 vs. 38.2 ± 20.76, P =0.043). There was
a positive correlation between galectin-3 protein and
MVD (P = 0.001, R = 0.265).
Downregulation and overexpression of galectin-3 by
using siRNA and Recombinant Lentivirus vector
To explore the function of galectin-3 in HCC progression,
we transfected gal-siRNA and negative control siRNA into
four HCC cell lines (HepG2, Bel-7402, Hep3B, Huh7). Si-
lencing efficiency in galectin-3-siRNA transfected cells
were verified by Western blotting (Figure 3A). Meanwhile,
the Hep3B cells were infected with galectin-3 -vector and
control-vector. Galectin-3 expression in the infected cells
was confirmed by western blot (Figure 3A).
The role of galectin-3 in cell proliferation and cycle
To investigate the effect of galectin-3 expression on cell
proliferation, we assessed the proliferation rates of control-al in hepatocellular carcinoma
Multivariate analyses
p HR 95% CI p
0.049a 1.008 0.997–1.018 0.145
<0.01a 7.506 3.000–18.779 <0.01a
0.385
0.572
0.005a 2.019 1.333–3.058 0.001a





Figure 3 (See legend on next page.)
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Figure 3 The effect of galectin-3 knockdown in the viability of HCC cells. (A) Western blot analysis showing expression of galectin-3 in
galectin-3-transfected cells. Expression of GAPDH was used as a loading control. (B) The MTS assay showed that silence of galectin-3 inhibited
the proliferation of HepG2, Bel-7402, Hep3B and Huh7 cells (*P < 0.05, independent Student’s t-test). (C) Rate of cell growth between galectin-3-
overexpresion and negative vector -transfected cells by MTT assay. Galectin-3 promoted cell proliferation in Hep3B cells (*P < 0.05, independent
Student’s t-test). (D) The effect of galectin-3 on cell cycle in HCC cells. The cells were transfected with gal-siRNA or negative control as in D. After
36 hours, the cells were collected for cell cycle distribution analysis. DNA content of gal-siRNA or negative control-transfected cells were detected
by flow cytometry. Knockdown of galectin-3 expression did not significantly change the G1, S, or G2 level of HCC cells. Experiments were
performed in triplicate times. (E) Overexpression of galectin-3 did not significantly change the G1, S, or G2 level of Hep3B cells. Experiments were
performed in triplicate times.
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http://www.translational-medicine.com/content/12/1/273and gal-siRNA-HepG2, Bel-7402, Huh7 as well as Hep3B
cells with a MTS assay. We detected a significant de-
crease in the proliferation rate of cells transfected with
gal-siRNA compared with the rate of the control cells at
days 3–7 (P < 0.05) (Figure 3B). In contrast, Hep3B cells
transfected with overexpression vector significantly in-
creased cell proliferation compared to the control vector
(Figure 3C). Furthermore, to ascertain the reason for the
restraint in cell growth, the cell-cycle distribution was de-
termined by flow cytometry. The cells were collected for
cell cycle distribution analysis after 36 hours, DNA con-
tent of gal-siRNA or negative control- transfected cells
were detected by flow cytometry. As shown in Figure 3D,
silenced galectin-3 expression did not significantly
change the G1, S, or G2 levels in HCC cells, including in
HepG2, Bel7402, Hep3B and Huh7 cells. This tendency
was also found in the Hep3B cells with galectin-3 overex-
pression vector (Figure 3E).
The role of Galectin-3 in cell apoptosis
The next question was whether the effect of galectin-3
knockdown on the inhibition of cell growth was associ-
ated with an induction of apoptosis. We then used the
Annexin V-FITC binding assay to explore the effects of
galectin-3 on apoptosis in HCC cells. After 72 hours, the
cells were collected for apoptosis analysis. The percent-
ages of Annexin-V or propidium iodide-positive cells
were detected by flow cytometry. Analysis of the propor-
tion of apoptotic cells revealed that a statistical differ-
ence between gal-siRNA cells and negative control cells
were observed (Figure 4A), Silence of galectin-3 caused
an increase in the percentage of apoptotic HCC cells.
Furthermore, galectin-3 overexpression resulted in a de-
crease of apoptosis (Figure 4B). These results suggest
that galectin-3 may play an important anti-apoptotic role
in HCC development. Caspase activation is an important
event in the apoptosis signaling pathway. Thus, to
confirm the mechanism of galectin-3 knockdown on
apoptosis, we detected the mRNA expression of certain
pro-apoptotic proteins and anti-apoptotic proteins, PARP,
caspase-3/9, BAX, and Bcl-2 by Real-time PCR. As shown
in Figure 5C, galectin-3 knockdown markedly induced the
activation of PARP and caspase-3/9, resulting in an in-
crease of the mRNA levels in PARP and caspase-3/9.Galectin-3 knockdown also increased the expression of
the pro-apoptotic protein BAX and suppressed the ex-
pression of the anti-apoptotic protein Bcl-2. To verify
the results observed in real-time PCR, we further ex-
amined the protein expression levels by western blot-
ting. In accordance with previous findings, knockdown
of galectin-3 markedly induced the activation of caspase-
3/9, resulting in an increase in the levels of PARP, caspase-
3/9, BAX proteins (Figure 4C).
The role of Galectin-3 in cell migration and invasion in
HCC cells
Previous studies have shown that galectin-3 expression
levels are correlated with tumor proliferation in cancer.
Hence, we examined the impact of galectin-3 knock-
down on the migration and invasion of HepG2, Bel-
7402, Hep3B, Huh7 cells. We employed a transwell assay
to evaluate the effects of galectin-3 expression on cell
migration. HepG2, Bel7402, Hep3B and Huh7 cells
infected with gal-siRNA migrated into the lower com-
partment of the migration chamber significantly less fre-
quently than did cells infected with the negative control
(Figure 5A). Wound-healing assays confirmed the inhibi-
tory effect of galectin-3 silence on cell migration. They
revealed that the time required for wound closure of
galectin-3-silenced HCC cells was significantly longer
than that required for the corresponding control cells
(Figure 5C).Consistent with the results of the migration
assay, galectin-3-siRNA also significantly inhibited cell
invasion through a Matrigel-coated membrane (Figure 6A).
In addition, we investigated the overexpression of
galectin-3 on the migration and invasion of Hep3B. The
wound-healing assay and cell migration assay revealed that
the ability of cell migration was increased when galectin-3
was overexpressed in Hep3B cells (Figure 5B and D). The
invasion results were consistent with the results of the mi-
gration assay (Figure 6B).
Discussion
Galectin-3 is a multifunctional member of the galectin
family. It plays an important part in the biological behav-
ior of various tumors and may have diagnostic and prog-
nostic significances [20-22]. Some recent reports have
showed an association between galectin-3 expression
Figure 4 Galectin-3 knockdown induced the apoptosis of HCC cells, and activates caspase-dependent apoptotic pathway. (A) Apoptosis
levels of gal-siRNA and negative control-transfected HCC cells were quantified with an Annexin V and propidium iodide viability assay. After
72 hours, the cells were collected for apoptosis analysis. The percentages of Annexin-V or propidium iodide-positive cells were detected by flow
cytometry. There were statistical differences between gal-siRNA cells and negative control cells. Experiments were performed in triplicate times
(*P < 0.05, independent Student’s t-test). (B) The galectin-3 overexpression in Hep3B inhibited the apoptosis. Experiments were performed in
triplicate times (*P < 0.05, independent Student’s t-test). (C) The protein and mRNA levels of PARP, caspase-3/9, BAX, and Bcl-2 proteins were
analyzed by western blotting and RT-PCR.
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sion is induced in cirrhotic livers and HCC [23] and that
galectin-3 overexpression inhibits the immune response
by inducing apoptosis in lymphocytes and thus promotes
tumor growth [24,25]. Taken together, these resultssuggest that the expression of galectin-3 has an import-
ant influence on the development of malignant tumors.
However, the clinical analysis and function of galectin-3
in HCC progression have rarely been discussed in the
literature.
Figure 5 Enforced expression of galectin-3 promoted HCC cell migration and metastatic capability. (A) Cell migration of HCC cells transfected
with gal-siRNA and negative control was evaluated with transwell migration assays. HCC cells infected with gal-siRNA migrated less than cells infected
with negative control. Representative images of migration cells are shown in the left panel and the results are summarized in the right panel. The results
are expressed as three independent experiments (*P < 0.05, independent Student’s t-test). (B) Transwell migration assay showing that galectin-3
promoted cell migration in Hep3B cells. (C) The migration ability of gal-siRNA and negative control-transfected HCC cells was determined by wound-
healing assay. Wound-closure time (measured after 24 h) was slower in cells transfected with gal-siRNA than in those transfected with negative control.
(D) Wound-healing assay showing that galectin-3 promoted cell migration in Hep3B cells. Representative images were taken at 24 hour after scratching.
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Figure 6 Galectin-3 overexpression promoted HCC cell invasion, whereas knockdown of galectin-3 suppressed these processes.
(A) Knockdown of galectin-3 significantly inhibited cell invasion in Bel-7402, HepG2 cells, Hep3B and Huh7 cells. Images are shown on the left
(magnification: ×100), and the quantification of 10 randomly selected fields is shown on the right. The results are expressed as three independent
experiments (*P < 0.05, independent Student t test). (B) Galectin-3 promoted cell invasion in Hep3B cells. The results are expressed as three
independent experiments (*P < 0.05, independent Student t test).
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and protein expression in 44 paired HCC tumors and
adjacent non-tumorous tissues and five HCC cell lines.
Most primary HCC tumor tissues showed significantly
upregulated galectin-3 expression relative to normal tis-
sues. This tendency was also verified in HCC cell lines.
In the immunostaining analyses, increased expression of
galectin-3 was found in 81.8% (135/165) of primaryHCC samples. The relationship between clinicopatholog-
ical features and galectin-3 expression showed that
galectin-3 expression was positively correlated with
serum AFP level (P < 0.01), but not with differential
stages. Our data are different from those of Shimose-
gawa et al. [19]. The reasons for these differences may
include different genetic backgrounds and a larger study
cohort (165 vs 52). Immunostaining analyses showed
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http://www.translational-medicine.com/content/12/1/273that increased expression of galectin-3 found in 81.8% of
primary HCC samples and was associated with serum
AFP levels. Furthermore, to evaluate the prognostic
value of galectin-3 expression in HCC patients, we divided
them into two subgroups (high galectin-3 expression and
low galectin-3 expression) and compared outcome be-
tween the two groups. The Kaplan–Meier survival analysis
revealed that patients with high galectin-3 expression had
a significantly shorter survival time than those with low
galectin-3 expression. In the multivariate analysis, we ob-
served that galectin-3 expression, together with some trad-
itional prognostic factors (tumor size, histologic grade)
were independent risk factors in the prognosis of HCC pa-
tients. Similar findings have been reported in other malig-
nancies [26-29].
The biological functions of galectin-3 in HCC are in-
completely understood. In the present study, we knocked
down and overexpressed the galectin-3 expression re-
spectively, and investigated its effects on the biological
behavior. Galectin-3 knockdown in HepG2, Bel-7402,
Hep3B and Huh7 cells contributed to inhibit the migra-
tion and invasion of cells, which suggested that galectin-3
was associated with metastatic events in HCC cells. Mean-
while, increased galectin-3 expression in the tumor cells
stimulates angiogenesis. MVD expression showed a sig-
nificant difference in the low and high galectin-3 groups.
There was a positive correlation between galectin-3 pro-
tein and MVD. Proliferation of blood vessels may provide
nutrients and pathways for tumor cells and improve its
ability of invasion and metastasis, thus affecting the bio-
logical behavior of Hepatocellular Carcinoma. This finding
is consistent with observations in other human cancers,
such as those in the breast, colon, and stomach [30-32].
Increasing evidence has shown that galectin-3 is impli-
cated in the modulation of growth of tumor cells.
Galectin-3 contributes to melanoma growth and metas-
tasis via regulation of NFAT1 and autotaxin, and
Galectin-3 regulates p21 stability in human prostate can-
cer cells [33,34]. In the present study, galectin-3 silence
in HCC cells reduced cell growth and induced apoptosis.
Cell growth differences between gal-siR NA, galectin-3-
overexpression cells and control cells in the MTS assay
were observed. It has been reported that Galectin-3 si-
lencing inhibits epirubicin-induced ATP binding cassette
transporters and activates the mitochondrial apoptosis
pathway via β-catenin/GSK-3β modulation in colorectal
carcinoma [35]. In this research, we found that the in-
duction of apoptosis in human HCC cancer cells by
galectin-3 silence was mediated by caspase-dependent
apoptosis pathways. Our results showed that knockdown
of galectin-3 induced the activation of caspase proteins.
It suggested that the antitumor effect of galectin-3
knockdown in HCC cells is associated with the increased
activation of caspase-dependent apoptotic pathway.Margadant C demonstrated that expression of galectin-3
specifically induced by β1 integrins promoted cell adhe-
sion and migration [36]. Zhang et al. found that silen-
cing of the galectin-3 gene inhibited the migration and
invasion of human tongue cancer cells in vitro via down-
regulation of beta-catenin [37]. In the present study, we
demonstrated that galectin-3 knockdown slowed the rate
of cell migration and decreased the extent of cell inva-
sion, which implies that it may have an oncogenic role
in HCC carcinogenesis. However, the underlying mech-
anism of how galectin-3 activates HCC needs further
research.
Conclusion
In conclusion, we demonstrated that galectin-3 expression
levels were increased in HCC, and might be associated
with metastasis and cell growth during the progression of
HCC. Hence, galectin-3 might serve as a prognostic factor
for HCC and have an important role in the diagnosis and
treatment of this disease.
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